Immunologic-mediated protection of Trypanosoma congolense-infected mice by polyribonucleotides.
D000227:Adenine Nucleotides / Q000627:therapeutic use; D000818:Animals; D003520:Cyclophosphamide; D003597:Cytosine Nucleotides / Q000627:therapeutic use; D005260:Female; D007165:Immunosuppression Therapy; D007274:Injections, Intraperitoneal; D007292:Inosine Nucleotides / Q000627:therapeutic use; D007372:Interferons; D008722:Methods; D051379:Mice; D009522:Newcastle disease virus; D011119:Polynucleotides / Q000627:therapeutic use*; D051381:Rats; D012265:Ribonucleotides / Q000627:therapeutic use; D012672:Semliki forest virus; D013997:Time Factors; D014345:Trypanosoma / Q000276:immunology*; D014352:Trypanosomiasis / Q000517:prevention & control*; D014500:Uracil Nucleotides / Q000627:therapeutic use; D014762:Viral Interference
D000227:Adenine Nucleotides; D003597:Cytosine Nucleotides; D007292:Inosine Nucleotides; D011119:Polynucleotides; D012265:Ribonucleotides; D014500:Uracil Nucleotides; D003520:Cyclophosphamide; D007372:Interferons